Cette page a été traduite automatiquement et l'exactitude de la traduction n'est pas garantie. Veuillez vous référer au version anglaise pour un texte source.

Riociguat chez les enfants atteints d'hypertension artérielle pulmonaire (HTAP) (PATENT-CHILD)

27 août 2026 mis à jour par: Bayer

Étude ouverte de titration de dose individuelle pour évaluer l'innocuité, la tolérabilité et la pharmacocinétique du riociguat chez les enfants de 6 à moins de 18 ans atteints d'hypertension artérielle pulmonaire (HTAP)

This study was designed to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of riociguat at age-, sex- and body-weight-adjusted doses of 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID in children from ≥6 to less than 18 years with pulmonary arterial hypertension (PAH) group 1. The study design consisted of a main study part followed by an optional long-term extension part. The main treatment period consisted of two phases: titration phase up to 8 weeks and a maintenance phase up to 16 weeks.

Aperçu de l'étude

Statut

Actif, ne recrute pas

Les conditions

Type d'étude

Interventionnel

Inscription (Réel)

24

Phase

  • Phase 3

Contacts et emplacements

Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.

Lieux d'étude

    • Baden-Wurttemberg
      • Heidelberg, Baden-Wurttemberg, Allemagne, 69115
        • Universitätsklinikum Heidelberg
      • Ulm, Baden-Wurttemberg, Allemagne, 89075
        • Universitätsklinikum Ulm
    • State of Berlin
      • Berlin, State of Berlin, Allemagne, 13353
        • Deutsches Herzzentrum der Charité (DHZC)
    • Valle del Cauca Department
      • Cali, Valle del Cauca Department, Colombie, 760042
        • Clínica Imbanaco S.A.S
    • Budapest
      • Budapest, Budapest, Hongrie, 1096
        • Gottsegen Gyorgy Orszagos Kardiovaszkularis Intezet
    • Csongrád-Csanád
      • Szeged, Csongrád-Csanád, Hongrie, 6720
        • Szegedi Tudományegyetem Szent-Györgyi Albert Klinikai Központ
    • Veneto
      • Padova, Veneto, Italie, 35128
        • Azienda Ospedale-Università di Padova - UOC Cardiologia Pediatrica
    • Aichi-ken
      • Ōbu, Aichi-ken, Japon, 474-8710
        • Aichi Children's Health and Medical Center
    • Osaka
      • Suita, Osaka, Japon, 565-8565
        • National Cerebral and Cardiovascular Center
      • Suita, Osaka, Japon, 565-0871
        • The University of Osaka Hospital
    • Tokyo
      • Shinjuku-ku, Tokyo, Japon, 160-8582
        • Keio University Hospital
    • Mexico City
      • México D.F., Mexico City, Mexique, 14080
        • Instituto Nacional de Cardiología "Ignacio Chávez"
    • State of Mexico
      • Huixquilucan, State of Mexico, Mexique, 52763
        • Operadora de Hospitales Angeles S. A. de C. V.
      • Wroclaw, Pologne, 51-124
        • Wojewodzki Szpital Specjalistyczny - Wroclaw
    • Kaohsiung
      • Kaohsiung City, Kaohsiung, Taïwan, 813414
        • Veterans General Hospital
      • Ankara, Turquie (Türkiye), 06230
        • Hacettepe Universitesi Tip Fakultesi

Critères de participation

Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.

Critère d'éligibilité

Âges éligibles pour étudier

6 ans à 17 ans (Enfant)

Accepte les volontaires sains

Non

Sexes éligibles pour l'étude

Tout

La description

Inclusion Criteria:

  • Children from 6 years to less than 18 years of age with pulmonary arterial hypertension (PAH)

  • Diagnosed with PAH :

    • Idiopathic (IPAH)

    • Hereditable (HPAH)

    • PAH associated with (APAH)

      • Connective tissue disease
      • Congenital heart disease with shunt closure more than 6 months ago (no open shunts, confirmed by RHC no less than 4 months after surgery)

Regardless of the type of PAH, the following findings are not exclusionary:

--- Patent foramen ovale (PFO) and asymptomatic, isolated, ostium secundum atrial septal defect (OS-ASD) ≤ 1 cm (both confirmed by echocardiogram) and not associated with hemodynamic alterations indicative of significant shunt, e.g. Qp/Qs ratio less <1.5:1 are not exclusionary

  • PAH diagnosed by right heart catheterization (RHC) at any time prior to enrolment (for patients with closed shunts - RHC no less than 4 months after surgery)
  • PAH confirmed by a RHC at any time prior to start of study, with mean pulmonary artery pressure (PAPmean) ≥25 mmHg at rest, pulmonary capillary wedge pressure (PCWP) or left ventricular end-diastolic pressure (LVEDP) ≤15 mmHg, and pulmonary vascular resistance (PVR) >240 dyn•sec•cm^-5 (i.e., ≥3.0 wood units•m^2)
  • Patients must be on standard of care PAH medications, allowing Endothelin Receptor Antagonists (ERA) and/or Prostacyclin Analogues (PCA), for at least 12 weeks prior to baseline visit.

Two groups of patients will be included:

  • Prevalent: Patients currently on PAH medication (allowing ERA and/or PCA) who need additional treatment (discretion of the investigator)

  • Incident: Treatment naïve patients initiated on PAH medication (allowing ERA and /or PCA) and then riociguat added once patients are stable on standard of care

    • WHO functional class I-III
    • Adolescent females of childbearing potential can only be included in the study if a pregnancy test is negative. Adolescent females of childbearing potential must agree to receive sexual counseling and use effective contraception as applicable. 'Effective contraception' is defined as progestogen-only hormonal contraception associated with inhibition of ovulation (implant), intrauterine device (IUD), intrauterine hormone-releasing system (IUS), or any combination of adequate methods of birth control (e.g. condoms with hormonal contraception). Agreement to use contraception is required from the signing of the informed consent form up until 4 weeks after the last study drug administration.
    • Young men must agree to use adequate contraception when sexually active.
    • Written inform consent provided and if applicable child assent provided

Exclusion Criteria:

  • Concomitant use of the following medications: phosphodiesterase (PDE) 5 inhibitors (such as sildenafil, tadalafil, vardenafil) and non-specific phosphodiesterase (PDE) inhibitors (theophylline, dipyridamole), nitrates or NO donors (such as amyl nitrite) in any form

    -- Pretreatment with NO donors (e.g. nitrates) within the last 2-weeks before visit 1. The use of any drug including NO acutely for testing during catheterization is not an exclusion criterion.

  • Active state of hemoptysis or pulmonary hemorrhage, including those events managed by bronchial artery embolization or any history of bronchial artery embolization or massive hemoptysis within 3 months prior to screening

  • Systolic blood pressure (SBP) more than 5 mmHg lower than the age-, sex- and height-adapted level of the 50th SBP percentile (NHBPEP, 2004)

  • History of left-sided heart disease, including valvular disease or heart failure

  • Pulmonary hypertension related to conditions other than specified in the inclusion criteria

  • WHO functional class IV

  • Pulmonary veno-occlusive disease

  • Screening aspartate transaminase (AST) and/ or alanine transaminase (ALT) more than 3 times the upper limit of normal (ULN)

  • Severe restrictive lung disease

  • Severe congenital abnormalities of the lung, thorax, and diaphragm

  • Clinically relevant hepatic dysfunction (especially Child Pugh C)

  • Renal insufficiency (estimated glomerular filtration rate <30 mL/min/1.73m^2 e.g. calculated based on Schwartz formula)

  • PH associated with idiopathic interstitial pneumonia (PH-IIP)

Plan d'étude

Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.

Comment l'étude est-elle conçue ?

Détails de conception

  • Objectif principal: Traitement
  • Répartition: N / A
  • Modèle interventionnel: Affectation à un seul groupe
  • Masquage: Aucun (étiquette ouverte)

Armes et Interventions

Groupe de participants / Bras
Intervention / Traitement
Expérimental: Riociguat

Participants with age ≥6 to <18 years received riociguat up to 2.5 mg three times a day (titration between 1.0 mg and 2.5 mg) for up to 8 weeks during the individual dose titration (IDT) phase, and followed with the last dose administered in the IDT phase for up to 16 weeks during the maintenance phase. Down-titration (up to 0.5 mg) of the dose for safety reasons was allowed at any time.

For children with body-weight <50 kg at screening: body-weight adjusted dose equivalent to the exposure of (0.5 mg) 1.0 - 2.5 mg three times a day, IDT in adults treated for PAH; oral suspension. For children ≥50 kg at screening: 1.0 to 2.5 mg three times a day; oral tablet.

Que mesure l'étude ?

Principaux critères de jugement

Mesure des résultats
Description de la mesure
Délai
Number of Participants With Any Treatment-emergent Adverse Events
Délai: From start of study drug up to 2 days after the last dose of study drug in the main study part, up to 24 weeks plus/minus 5 days.

An adverse event (AE), including AE in relation to a medical device (i.e. Raumedic dosing pipette), is any untoward medical occurrence in a participant administered with a pharmaceutical product and does not necessarily have to have a causal relationship with this treatment. A serious AE (SAE) is any untoward medical occurrence that at any dose is resulting in death, is lifethreatening, requires hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity. AEs occurring between start of study drug and up to 2 days after the last dose were defined as treatment-emergent AEs (TEAEs).

From start of study drug up to 2 days after the last dose of study drug in the main study part, up to 24 weeks plus/minus 5 days.
Change in Heart Rate From Baseline
Délai: Baseline and Week 24 (plus/minus 5 days)

Mean change in heart rate from baseline is reported.

Baseline and Week 24 (plus/minus 5 days)
Change in Blood Pressure From Baseline
Délai: Baseline and Week 24 (plus/minus 5 days)

Mean changes in systolic blood pressure (SBP) and diastolic blood pressure (DBP) from baseline are reported.

Baseline and Week 24 (plus/minus 5 days)
Change in Respiratory Rate From Baseline
Délai: Baseline and Week 24 (plus/minus 5 days)

Mean change in respiratory rate from baseline is reported.

Baseline and Week 24 (plus/minus 5 days)
Number of Subjects With Transitions From Baseline in Bone Age Compared to Chronological Age
Délai: Baseline and Week 24 (plus/minus 5 days)

X-ray of left hand was performed for each participant and bone age was determined centrally by a specialist. For each participant, the bone age was compared to the chronological age and assigned to one of the categories - "delayed", "in accordance" or "advanced", indicating the advancement or delay in the growth of the bone. Number of participants who transitioned to another category different from baseline was calculated and is reported.

Baseline and Week 24 (plus/minus 5 days)
Change in Hematology Parameters (Platelets) From Baseline
Délai: Baseline and Week 24 (plus/minus 5 days)

Hematology parameters were collected. Parameters with a decrease or increase in the mean value compared to baseline are reported in this data set.

Baseline and Week 24 (plus/minus 5 days)
Change in Hematology Parameters (Lymphocytes/Leucocytes Ratio) From Baseline
Délai: Baseline and Week 24 (plus/minus 5 days)

Hematology parameters were collected. Parameters with a decrease or increase in the mean value compared to baseline are reported in this data set.

Baseline and Week 24 (plus/minus 5 days)
Change in Hematology Parameter (Neutrophils/Leucocytes Ratio) From Baseline
Délai: Baseline and Week 24 (plus/minus 5 days)

Hematology parameters were collected. Parameters with a decrease or increase in the mean value compared to baseline are reported in this data set.

Baseline and Week 24 (plus/minus 5 days)
Change in Clinical Chemistry (Alanine Aminotransferase) From Baseline
Délai: Baseline and Week 24 (plus/minus 5 days)

Clinical chemistry parameters were collected and analyzed. Parameters with a trend to lower or higher mean values from baseline are reported in this data set.

Baseline and Week 24 (plus/minus 5 days)
Change in Clinical Chemistry (Aspartate Aminotransferase) From Baseline
Délai: Baseline and Week 24 (plus/minus 5 days)

Clinical chemistry parameters were collected and analyzed. Parameters with a trend to lower or higher mean values from baseline are reported in this data set.

Baseline and Week 24 (plus/minus 5 days)
Change in Clinical Chemistry (Sodium) From Baseline
Délai: Baseline and Week 24 (plus/minus 5 days)

Clinical chemistry parameters were collected and analyzed. Parameters with a trend to lower or higher mean values from baseline are reported in this data set.

Baseline and Week 24 (plus/minus 5 days)
Change in Clinical Chemistry (Blood Urea Nitrogen) From Baseline
Délai: Baseline and Week 24 (plus/minus 5 days)

Clinical chemistry parameters were collected and analyzed. Parameters with a trend to lower or higher mean values from baseline are reported in this data set.

Baseline and Week 24 (plus/minus 5 days)
Change in Clinical Chemistry (eGFR) From Baseline
Délai: Baseline and Week 24 (plus/minus 5 days)

Clinical chemistry parameters were collected and analyzed. Parameters with a trend to lower or higher mean values from baseline are reported in this data set. eGFR = estimated glomerular filtration rate

Baseline and Week 24 (plus/minus 5 days)
Change in Clinical Chemistry (Urea) From Baseline
Délai: Baseline and Week 24 (plus/minus 5 days)

Clinical chemistry parameters were collected and analyzed. Parameters with a trend to lower or higher mean values from baseline are reported in this data set.

Baseline and Week 24 (plus/minus 5 days)
Change in Clinical Chemistry (Gamma Glutamyl Transferase) From Baseline
Délai: Baseline and Week 24 (plus/minus 5 days)

Clinical chemistry parameters were collected and analyzed. Parameters with a trend to lower or higher mean values from baseline are reported in this data set.

Baseline and Week 24 (plus/minus 5 days)
Plasma Concentration of Riociguat at Week 0
Délai: Week 0 (30-90 minutes post-dose; 2.5-4 hours post-dose)

For each participant, one blood sample was collected at one given time point. Values below lower limit of quantification (LLOQ) were substituted by 1/2 LLOQ for the calculation in statistics. Means at any time were only calculated if at least 2/3 of the individual data were measured and were above the limit of quantification (LOQ). Geometric mean and percentage geometric coefficient of variation (%CV) are reported. W = Week.

Week 0 (30-90 minutes post-dose; 2.5-4 hours post-dose)
Plasma Concentration of Riociguat at Week 4
Délai: Week 4 (pre-dose)

For each participant, one blood sample was collected at one given time point. Values below lower limit of quantification (LLOQ) were substituted by 1/2 LLOQ for the calculation in statistics. Means at any time were only calculated if at least 2/3 of the individual data were measured and were above the limit of quantification (LOQ). Geometric mean and percentage geometric coefficient of variation (%CV) are reported.

Week 4 (pre-dose)
Plasma Concentration of Riociguat at Week 8
Délai: Week 8 (pre-dose)

For each participant, one blood sample was collected at one given time point. Values below lower limit of quantification (LLOQ) were substituted by 1/2 LLOQ for the calculation in statistics. Means at any time were only calculated if at least 2/3 of the individual data were measured and were above the limit of quantification (LOQ). Geometric mean and percentage geometric coefficient of variation (%CV) are reported.

Week 8 (pre-dose)
Plasma Concentration of BAY60-4552 at Week 0
Délai: Week 0 (30-90 minutes post-dose; 2.5-4 hours post-dose)

BAY60-4552 is riociguat's active metabolite. For each participant, one blood sample was collected at one given time point and in that sample both riociguat and BAY60-4552 were measured. Values below lower limit of quantification (LLOQ) were substituted by 1/2 LLOQ for the calculation in statistics. Means at any time were only calculated if at least 2/3 of the individual data were measured and were above the limit of quantification (LOQ). Geometric mean and percentage geometric coefficient of variation (%CV) are reported. W = Week

Week 0 (30-90 minutes post-dose; 2.5-4 hours post-dose)
Plasma Concentration of BAY60-4552 at Week 4
Délai: Week 4 (pre-dose)

BAY60-4552 is riociguat's active metabolite. For each participant, one blood sample was collected at one given time point and in that sample both riociguat and BAY60-4552 were measured. Values below lower limit of quantification (LLOQ) were substituted by 1/2 LLOQ for the calculation in statistics. Means at any time were only calculated if at least 2/3 of the individual data were measured and were above the limit of quantification (LOQ). Geometric mean and percentage geometric coefficient of variation (%CV) are reported.

Week 4 (pre-dose)
Plasma Concentration of BAY60-4552 at Week 8
Délai: Week 8 (pre-dose)

BAY60-4552 is riociguat's active metabolite. For each participant, one blood sample was collected at one given time point and in that sample both riociguat and BAY60-4552 were measured. Values below lower limit of quantification (LLOQ) were substituted by 1/2 LLOQ for the calculation in statistics. Means at any time were only calculated if at least 2/3 of the individual data were measured and were above the limit of quantification (LOQ). Geometric mean and percentage geometric coefficient of variation (%CV) are reported.

Week 8 (pre-dose)

Mesures de résultats secondaires

Mesure des résultats
Description de la mesure
Délai
Change in 6-minute Walking Distance From Baseline
Délai: Baseline and Week 24 (plus/minus 5 days)

6-minute walking distance (6MWD) is a exercise test used to assess aerobic capacity and endurance. The distance covered over a time of 6 minutes is used as the outcome by which to compare changes in performance capacity. An increase in the distance walked indicates improvement in basic mobility.

Baseline and Week 24 (plus/minus 5 days)
Number of Subjects With Change in WHO Functional Class From Baseline
Délai: Baseline and Week 24 (plus/minus 5 days)

The World Health Organization (WHO) functional class describes how severe a patient's pulmonary hypertension (PH) symptoms are. There are four different classes - I is the mildest and IV the most severe form of PH. Number of participants per change in number of classes is reported.

Baseline and Week 24 (plus/minus 5 days)
Change in NT-proBNP From Baseline
Délai: Baseline and Week 24 (plus/minus 5 days)

Laboratory biomarkers N-terminal prohormone brain-type natriuretic peptide (NT-proBNP) or brain-type natriuretic peptide (BNP) were tested for the participants. When both tests were available, NT-proBNP was chosen over BNP and the same test was performed at every required visit.

Baseline and Week 24 (plus/minus 5 days)
Change in BNP From Baseline
Délai: Baseline and Week 24 (plus/minus 5 days)

Laboratory biomarkers N-terminal prohormone brain-type natriuretic peptide (NT-proBNP) or brain-type natriuretic peptide (BNP) were tested for the participants. When both tests were available, NT-proBNP was chosen over BNP and the same test was performed at every required visit.

Baseline and Week 24 (plus/minus 5 days)
Change in Quality of Life Evaluated by SF-10 Questionnaire From Baseline
Délai: Baseline and Week 24 (plus/minus 5 days)

SF-10 is a parent-completed health survey for children that contains 10 questions adapted from the Child Health Questionnaire. It is scored using nom-based scoring to produce physical and psychosocial health summary measures. The possible range for the physical measure is -10.9 to 57.2 scores and the possible range for the psychosocial measure is 8.8 to 62.3 scores. Higher scores indicate more favorable functioning.

Baseline and Week 24 (plus/minus 5 days)
Change in Quality of Life Evaluated by PedsQL Scale
Délai: Baseline and Week 24 (plus/minus 5 days)

The PedsQL Generic Core Scales were designed to measure health-related quality of life in children and adolescents. It has 4 dimensions: physical functioning, emotional functioning, social functioning and school functioning. 3 Summary Scores of PedsQL were calculated from the scales including total scale score (23 questions), physical health summary score (physical functioning, 8 questions) and psychosocial health summary score (emotional, social and school functioning, 15 questions). Responses of the questions are transformed to a 0-100 scale. Higher scores indicate better quality of life.

Baseline and Week 24 (plus/minus 5 days)
Number of Subjects With Clinical Worsening
Délai: Up to Week 24 (plus/minus 5 days)

Clinical worsening was defined as: hospitalization for right heart failure, death, lung transplantation, Pott's anastomosis and atrioseptostomy, worsening of pulmonary arterial hypertension (PAH) symptoms, which must include either an increase in World Health Organization (WHO) functional class or appearance/worsening symptoms of right heart failure and need for additional PAH therapy.

Up to Week 24 (plus/minus 5 days)
Change in Estimated Right Atrial Pressure From Baseline
Délai: Baseline and Week 24 (plus/minus 5 days)

Estimated right atrial pressure was measured by echocardiography.

Baseline and Week 24 (plus/minus 5 days)
Change in Left Ventricular Eccentricity Index From Baseline
Délai: Baseline and Week 24 (plus/minus 5 days)

Left ventricular (LV) eccentricity index (EI) was measured by echocardiography and defined as the ratio of the LV anteroposterior dimension to the septolateral dimension in the parasternal short-axis window by echocardiography. The value of EI greater than 1.0 is abnormal and suggests right ventricle (RV) overload.

Baseline and Week 24 (plus/minus 5 days)
Change in Pericardial Effusion From Baseline
Délai: Baseline and Week 24 (plus/minus 5 days)

Pericardial effusion was measured by echocardiography.

Baseline and Week 24 (plus/minus 5 days)
Change in Pulmonary Artery Acceleration Time From Baseline
Délai: Baseline and Week 24 (plus/minus 5 days)

Pulmonary artery acceleration time was measured by echocardiography.

Baseline and Week 24 (plus/minus 5 days)
Change in Right Ventricular Cardiac Index From Baseline
Délai: Baseline and Week 24 (plus/minus 5 days)

Right ventricle (RV) cardiac index (CI) was measured by echocardiography and calculated by dividing the cardiac output (stroke volume × heart rate) by the body surface area. The change in RV CI should not be understood solely but associated with other conditions of the participants.

Baseline and Week 24 (plus/minus 5 days)
Change in Right Ventricular Cardiac Output From Baseline
Délai: Baseline and Week 24 (plus/minus 5 days)

Right ventricular cardiac output was measured by echocardiography.

Baseline and Week 24 (plus/minus 5 days)
Change in Right Atrial Diastolic Area From Baseline
Délai: Baseline and Week 24 (plus/minus 5 days)

Right atrial diastolic area was measured by echocardiography.

Baseline and Week 24 (plus/minus 5 days)
Change in Right Atrial Diastolic Area Index From Baseline
Délai: Baseline and Week 24 (plus/minus 5 days)

Right atrial (RA) diastolic area index was measured by echocardiography and calculated by dividing the RA area at end-diastole by the body surface area. The RA area index is a reflection of RA volume at end-diastole. The change in the index should not be understood solely but associated with other conditions of the participants.

Baseline and Week 24 (plus/minus 5 days)
Change in Right Atrial Systolic Area From Baseline
Délai: Baseline and Week 24 (plus/minus 5 days)

Right atrial systolic area was measured by echocardiography.

Baseline and Week 24 (plus/minus 5 days)
Change in Right Atrial Systolic Area Index From Baseline
Délai: Baseline and Week 24 (plus/minus 5 days)

Right atrial (RA) systolic area index was measured by echocardiography and calculated by dividing the RA area at end-systole by the body surface area. The RA area index is a reflection of RA volume at end-systole. The change in the index should not be understood solely but associated with other conditions of the participants.

Baseline and Week 24 (plus/minus 5 days)
Change in Right Ventricular Fractional Area Change From Baseline
Délai: Baseline and Week 24 (plus/minus 5 days)

Right ventricular fractional area change was measured by echocardiography.

Baseline and Week 24 (plus/minus 5 days)
Change in Right Ventricular Diastolic Area From Baseline
Délai: Baseline and Week 24 (plus/minus 5 days)

Right ventricular diastolic area was measured by echocardiography.

Baseline and Week 24 (plus/minus 5 days)
Change in Right Ventricular Diastolic Area Index From Baseline
Délai: Baseline and Week 24 (plus/minus 5 days)

Right ventricular (RV) diastolic area index was measured by echocardiography and calculated by dividing the RV area at end-diastole by the body surface area. The RV area index is a reflection of RV volume at end-diastole. The change in the index should not be understood solely but associated with other conditions of the participants.

Baseline and Week 24 (plus/minus 5 days)
Change in Right Ventricular Systolic Area From Baseline
Délai: Baseline and Week 24 (plus/minus 5 days)

Right ventricular systolic area was measured by echocardiography.

Baseline and Week 24 (plus/minus 5 days)
Change in Right Ventricular Systolic Area Index From Baseline
Délai: Baseline and Week 24 (plus/minus 5 days)

Right ventricular (RV) systolic area index was measured by echocardiography and calculated by dividing the RV area at end-systole by the body surface area. The RV area index is a reflection of RV volume at end-systole. The change in the index should not be understood solely but associated with other conditions of the participants.

Baseline and Week 24 (plus/minus 5 days)
Change in Systolic Pulmonary Artery Pressure From Baseline
Délai: Baseline and Week 24 (plus/minus 5 days)

Systolic pulmonary artery pressure was measured by echocardiography.

Baseline and Week 24 (plus/minus 5 days)
Change in Tricuspid Annular Plane Systolic Excursion From Baseline
Délai: Baseline and Week 24 (plus/minus 5 days)

Tricuspid annular plane systolic excursion (TAPSE) was measured by echocardiography.

Baseline and Week 24 (plus/minus 5 days)
Change in Tricuspid Regurgitation Peak Velocity From Baseline
Délai: Baseline and Week 24 (plus/minus 5 days)

Tricuspid regurgitation peak velocity was measured by echocardiography.

Baseline and Week 24 (plus/minus 5 days)

Autres mesures de résultats

Mesure des résultats
Description de la mesure
Délai
Taste and Texture (Questions 1 to 4) of the Oral Suspension of Riociguat at Week 0
Délai: At the beginning of the treatment (Week 0)

To assess the taste and texture of oral suspension of Riociguat, a questionnaire including 7 questions was used. Responses to Questions 1 to 4 are reported in this endpoint. Questions 1 and 2 were asked before the participants received the suspension; whereas questions 3 and 4 were asked right after administration of the suspension. Participants were asked to respond to the 4 questions as "yes" (= positive answer), "I do not know/unsure"(= indifferent answer) or "No" (= negative answer).

At the beginning of the treatment (Week 0)
Taste and Texture (Questions 1 to 4) the Oral Suspension of Riociguat at Week 24
Délai: Week 24 (plus/minus 5 days)

To assess the taste and texture of oral suspension of Riociguat, a questionnaire including 7 questions was used. Responses to Questions 1 to 4 are reported in this endpoint. Questions 1 and 2 were asked before the participants received the suspension; whereas questions 3 and 4 were asked right after administration of the suspension. Participants were asked to respond to the 4 questions as "yes" (= positive answer), "I do not know/unsure"(= indifferent answer) or "No" (= negative answer).

Week 24 (plus/minus 5 days)
Taste and Texture (Question 5) of the Oral Suspension of Riociguat at Week 0
Délai: At the beginning of the treatment (Week 0)

To assess the taste and texture of oral suspension of Riociguat, a questionnaire including 7 questions was used. Number of participants per responses to Questions 5 "Taste of the drink" is reported in this endpoint. Question 5 was only asked to participants who answered "No" to Question 3 "Did you like the drink" or Question 4 "Would you like to drink this again". Participants were asked to answer "yes", "I do not know/unsure" or "No" to each taste including "sweet, sour, bitter, salty, disgusting and fruity".

At the beginning of the treatment (Week 0)
Taste and Texture (Question 5) of the Oral Suspension of Riociguat at Week 24
Délai: Week 24 (plus/minus 5 days)

To assess the taste and texture of oral suspension of Riociguat, a questionnaire including 7 questions was used. Number of participants per responses to Questions 5 "Taste of the drink" is reported in this endpoint. Question 5 was only asked to participants who answered "No" to Question 3 "Did you like the drink" or Question 4 "Would you like to drink this again". Participants were asked to answer "yes", "I do not know/unsure" or "No" to each taste including "sweet, sour, bitter, salty, disgusting and fruity".

Week 24 (plus/minus 5 days)
Taste and Texture (Question 6) of the Oral Suspension of Riociguat at Week 0
Délai: At the beginning of the treatment (Week 0)

To assess the taste and texture of oral suspension of Riociguat, a questionnaire including 7 questions was used. Number of participants per responses to Questions 6 "Drink feels in mouth" is reported in this endpoint. Question 6 was only asked to participants who answered "No" to Question 3 "Did you like the drink" or Question 4 "Would you like to drink this again". Participants were asked to answer "yes", "I do not know/unsure" or "No" to each feeling including "like sand, sticky, gooey, slimy, creamy".

At the beginning of the treatment (Week 0)
Taste and Texture (Question 6) of the Oral Suspension of Riociguat in Mouth at Week 24
Délai: Week 24 (plus/minus 5 days)

To assess the taste and texture of oral suspension of Riociguat, a questionnaire including 7 questions was used. Number of participants per responses to Questions 6 "Drink feels in mouth" is reported in this endpoint. Question 6 was only asked to participants who answered "No" to Question 3 "Did you like the drink" or Question 4 "Would you like to drink this again". Participants were asked to answer "yes", "I do not know/unsure" or "No" to each feeling including "like sand, sticky, gooey, slimy, creamy".

Week 24 (plus/minus 5 days)
Taste and Texture (Question 7) of the Oral Suspension of Riociguat in Mouth at Week 0
Délai: At the beginning of the treatment (Week 0)

To assess the taste and texture of oral suspension of Riociguat, a questionnaire including 7 questions was used. Number of participants per responses to Questions 7 "Did you like the taste after swallowing" is reported in this endpoint. Question 7 was only asked to participants who answered "No" to Question 3 "Did you like the drink" or Question 4 "Would you like to drink this again". Participants were asked to respond as "yes" (= positive answer), "I do not know/unsure"(= indifferent answer) or "No" (= negative answer).

At the beginning of the treatment (Week 0)
Taste and Texture (Question 7) of the Oral Suspension of Riociguat in Mouth at Week 24
Délai: Week 24 (plus/minus 5 days)

To assess the taste and texture of oral suspension of Riociguat, a questionnaire including 7 questions was used. Number of participants per responses to Questions 7 "Did you like the taste after swallowing" is reported in this endpoint. Question 7 was only asked to participants who answered "No" to Question 3 "Did you like the drink" or Question 4 "Would you like to drink this again". Participants were asked to respond as "yes" (= positive answer), "I do not know/unsure"(= indifferent answer) or "No" (= negative answer).

Week 24 (plus/minus 5 days)
Expression Assessment on the Taste and Texture of Oral Suspension of Riociguat - Week 0
Délai: At the beginning of the treatment (Week 0)

The facial expression of the subjects concerning appearance, smell and taste of the suspension of Riociguat was captured by the investigators as "comfortable", "indifferent" and "displeased".

At the beginning of the treatment (Week 0)
Expression Assessment on the Taste and Texture of Oral Suspension of Riociguat - Week 24
Délai: Week 24 (plus/minus 5 days)

The facial expression of the subjects concerning appearance, smell and taste of the suspension of Riociguat was captured by the investigators as "comfortable", "indifferent" and "displeased".

Week 24 (plus/minus 5 days)

Collaborateurs et enquêteurs

C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.

Parrainer

Collaborateurs

Les enquêteurs

  • Directeur d'études: Bayer Study Director, Bayer

Publications et liens utiles

La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.

Dates d'enregistrement des études

Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.

Dates principales de l'étude

Début de l'étude (Réel)

29 octobre 2015

Achèvement primaire (Réel)

7 mars 2020

Achèvement de l'étude (Estimé)

15 mai 2028

Dates d'inscription aux études

Première soumission

28 septembre 2015

Première soumission répondant aux critères de contrôle qualité

28 septembre 2015

Première publication (Estimé)

29 septembre 2015

Mises à jour des dossiers d'étude

Dernière mise à jour publiée (Réel)

23 septembre 2026

Dernière mise à jour soumise répondant aux critères de contrôle qualité

27 août 2026

Dernière vérification

1 août 2026

Plus d'information

Termes liés à cette étude

Autres numéros d'identification d'étude

  • 15681
  • 2014 (Subvention/contrat des NIH des États-Unis)
  • 2014-003952-29 (Numéro EudraCT)

Plan pour les données individuelles des participants (IPD)

Prévoyez-vous de partager les données individuelles des participants (DPI) ?

NON

Description du régime IPD

Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.

Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.

Informations sur les médicaments et les dispositifs, documents d'étude

Étudie un produit pharmaceutique réglementé par la FDA américaine

Oui

Étudie un produit d'appareil réglementé par la FDA américaine

Non

Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .

S'abonner